Treats hypertension. ANDA 213361, held by Aurobindo Pharma. Nifedipine.
As of Nov 16, 2026, ANDA 213361 (Nifedipine), held by Aurobindo Pharma, was first approved by FDA on Jul 19, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATION AND USAGE Nifedipine extended-release tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 19, 2021 | Original application | Approved | None posted |
| Nifedipine30MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine60MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine90MG · tablet, extended release;oral | Nifedipine | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters